AASLD 2018: AASLD Presidential Poster of Distinction
Abstract: #588 Eradication of Hepatitis C Virus Infection by IFN-Free Direct-Acting Antiviral Agents Reduces Hepatocellular Carcinoma Incidence in Patients with Chronic Hepatitis C – Hitomi Sezaki, et. al.
The risk of hepatocellular carcinoma (HCC or liver cancer) after being cured with direct-acting antiviral (DAA) treatment is still a hotly debated topic. This retrospective study analyzed records of 1,928 people cured with DAA therapy to 2,394 untreated chronic HCV patients (control group). The patient health and liver cancer history were recorded.
The DAA group had a cure rate of 92%. There were 677 in each group (DAA group and untreated group-patient characteristic were evenly matched). It was reported that the rate of HCC (liver cancer) in the DAA group was 1% at year 2, 2.1% at year 3 and 3.1% at year 4 vs. 2.6% at year 2, 5.9% at year 3, and 9.3% at year 4 in the untreated group.
Conclusion: DAA therapy significantly reduced the incidence of HCC at year one through year four after being cured of HCV.
Editorial Comments: Boy do I wish I had more information about this study. I can’t wait to read the entire publication to learn more. I hope to share the information when published. Until that time, it’s information that should comfort those who are cured (or those who are contemplating treatment with DAAs) that being cured will reduce the chances of developing HCC. Be sure to check out Lucinda Porter’s article in the next issue of the HCV Advocate newsletter.Share This Page